| 不良反应 | TMZ + APT (n = 43) | TMZ + BEV (n = 56) | c2值 | P | ||
| 1~2级 | 3~4级 | 1~2级 | 3~4级 | |||
| 骨髓抑制 | 7 (16.28%) | 10 (23.26%) | 15 (26.79%) | 4 (7.14%) | 1 | 0.039 |
| 恶心呕吐 | 15 (34.86%) | 7 (16.28%) | 18 (32.14%) | 5 (8.93%) | 1 | 0.514 |
| 乏力 | 18 (41.86%) | 5 (11.63%) | 15 (26.79%) | 10 (17.86%) | 1 | 0.221 |
| 高血压 | 15 (34.88%) | 4 (9.30%) | 3 (5.36%) | 6 (10.71%) | 1 | 0.035 |
| 转氨酶异常 | 5 (11.63%) | 2 (4.65%) | 1 (1.79%) | 0 (0.00%) | 1 | 1 |
| 出血 | 2 (4.65%) | 1 (2.33%) | 24 (42.86%) | 4 (7.14%) | 1 | 0.422 |
| 蛋白尿 | 13 (30.23%) | 7 (16.28%) | 9 (16.71%) | 12 (21.43%) | 1 | 0.215 |
| 血栓 | 0 (0.00%) | 0 (0.00%) | 3 (5.36%) | 2 (3.57%) | - | - |